down arrow

Ovid Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6904691010
USD
1.81
0.02 (1.12%)

Dec 23

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.671.81

52 Week

0.242.01
Valuation
Technical
Day's Volume

CASH

2.37 M

Shareholding (Mar 2025)

FII

16.51%

Held by 30 FIIs

DII

49.98%

Held by 20 DIIs

Promoter

19.36%

How big is Ovid Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Ovid Therapeutics, Inc. has a market capitalization of 21.50 million, with recent net sales of 0.55 million and a net profit of -24.97 million for the four quarters ending in March 2025. As of December 2024, the company reported shareholder's funds of 68.23 million and total assets of 92.17 million.

Market Cap: As of Jun 18, Ovid Therapeutics, Inc. has a market capitalization of 21.50 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, Ovid Therapeutics, Inc. reported net sales of 0.55 million and a net profit of -24.97 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 68.23 million and total assets of 92.17 million.

Read More

What does Ovid Therapeutics, Inc. do?

22-Jun-2025

Ovid Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare neurological disorders. It has a market cap of $21.50 million and reported net sales of $0 million with a net loss of $10 million as of March 2025.

Overview:<BR>Ovid Therapeutics, Inc. is a biopharmaceutical company engaged in developing medicines for patients and families living with rare neurological disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 21.50 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.70 <BR>Return on Equity: -33.92% <BR>Price to Book: 0.36<BR><BR>Contact Details:<BR>Address: 1460 Broadway Ste 15044, NEW YORK NY: 10036-7329 <BR>Tel: 1 646 6617661 <BR>Fax: 1 302 6365454 <BR>Website: http://www.ovidrx.com/

Read More

Who are in the management team of Ovid Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Ovid Therapeutics, Inc.'s management team includes Dr. Jeremy Levin as Chairman and CEO, Mr. Bart Friedman as Lead Independent Director, and Drs. Karen Bernstein, Barbara Duncan, and Douglas Williams as Independent Directors.

As of March 2022, the management team of Ovid Therapeutics, Inc. includes Dr. Jeremy Levin, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, Mr. Bart Friedman is the Lead Independent Director, while Dr. Karen Bernstein, Dr. Barbara Duncan, and Dr. Douglas Williams serve as Independent Directors.

Read More

Is Ovid Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of August 13, 2025, Ovid Therapeutics, Inc. is considered risky and overvalued due to negative financial indicators, including a price-to-book value of 0.38, an EV to EBITDA ratio of 0.34, a return on equity of -33.92%, and a significant underperformance of -81.76% over five years compared to the S&P 500's 96.61% return.

As of 13 August 2025, the valuation grade for Ovid Therapeutics, Inc. has moved from does not qualify to risky, indicating increased concerns about the company's financial health. Based on the available metrics, Ovid appears to be overvalued given its negative performance indicators, including a price-to-book value of 0.38 and an EV to EBITDA ratio of 0.34. The company also has a return on equity (ROE) of -33.92%, which further underscores its financial struggles.<BR><BR>When compared to peers, Ovid's valuation ratios are less favorable; for instance, KalVista Pharmaceuticals, Inc. has a more negative EV to EBITDA of -3.6594, while Fulcrum Therapeutics, Inc. does not qualify for valuation metrics. Additionally, Ovid's stock has underperformed relative to the S&P 500 over the long term, with a 5-year return of -81.76% compared to the S&P's 96.61%. This performance reinforces the notion that Ovid is currently overvalued in the market.

Read More

Is Ovid Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Ovid Therapeutics has shifted to a bullish trend with strong short-term performance, showing a 30.79% return over the past month, but it has underperformed the S&P 500 over the longer term with returns of -41.35% and -81.76% over 3 and 5 years, respectively.

As of 3 September 2025, the technical trend for Ovid Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by a bullish MACD on the weekly chart and a bullish daily moving average. The KST is also bullish on the weekly timeframe. However, the monthly MACD is only mildly bullish, and the Bollinger Bands indicate a bearish stance on the monthly level. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal.<BR><BR>In terms of performance, Ovid Therapeutics has shown a strong 30.79% return over the past month, significantly outperforming the S&P 500, which returned 2.33% in the same period. However, over longer periods, the stock has underperformed the benchmark, particularly over 3 years and 5 years, with returns of -41.35% and -81.76%, respectively, compared to the S&P 500's gains.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate 7.91% of over the last 5 years

 
2

Flat results in Jun 25

3

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 88 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.66

stock-summary
Return on Equity

-59.71%

stock-summary
Price to Book

1.58

Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
43.65%
0%
43.65%
6 Months
524.14%
0%
524.14%
1 Year
90.59%
0%
90.59%
2 Years
-47.23%
0%
-47.23%
3 Years
6.47%
0%
6.47%
4 Years
-46.61%
0%
-46.61%
5 Years
-32.71%
0%
-32.71%

Ovid Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Ovid Therapeutics Hits New 52-Week High at $2.01, Marking Significant Milestone

Ovid Therapeutics Hits New 52-Week High at $2.01, Marking Significant Milestone

Ovid Therapeutics, Inc. has achieved a new 52-week high of USD 2.01, recovering from a previous low of USD 0.24. Despite this milestone, the company has faced a challenging year with a significant performance decline. Ovid's market capitalization is USD 88 million, and it remains loss-making.

Read More
Ovid Therapeutics Hits New 52-Week High of $1.81, Marking Key Milestone

Ovid Therapeutics Hits New 52-Week High of $1.81, Marking Key Milestone

Ovid Therapeutics, Inc. has achieved a new 52-week high of USD 1.81, recovering from a low of USD 0.24. Despite this milestone, the company has faced a challenging year with a 44.19% decline in performance. Currently, it has a market capitalization of USD 88 million and is operating at a loss.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
50.22%
EBIT Growth (5y)
7.91%
EBIT to Interest (avg)
-27.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.70
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
88.54%
ROCE (avg)
0
ROE (avg)
12.05%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.38
EV to EBIT
0.33
EV to EBITDA
0.34
EV to Capital Employed
-1.08
EV to Sales
-18.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-33.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 29 Schemes (14.15%)

Foreign Institutions

Held by 30 Foreign Institutions (16.51%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 6,200.00% vs 0.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 53.92% vs -9.68% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.30",
          "val2": "0.10",
          "chgp": "6,200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.00",
          "val2": "-12.40",
          "chgp": "59.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.70",
          "val2": "-10.20",
          "chgp": "53.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-808.80%",
          "val2": "-96,538.50%",
          "chgp": "9,572.97%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 50.00% vs -73.33% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 49.52% vs 3.51% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.40",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-61.30",
          "val2": "-57.70",
          "chgp": "-6.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.30",
          "val2": "-0.80",
          "chgp": "-62.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.40",
          "val2": "-52.30",
          "chgp": "49.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-109,337.50%",
          "val2": "-151,346.00%",
          "chgp": "4,200.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
6.30
0.10
6,200.00%
Operating Profit (PBDIT) excl Other Income
-5.00
-12.40
59.68%
Interest
0.00
0.00
Exceptional Items
0.00
-0.10
100.00%
Consolidate Net Profit
-4.70
-10.20
53.92%
Operating Profit Margin (Excl OI)
-808.80%
-96,538.50%
9,572.97%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 6,200.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 53.92% vs -9.68% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.60
0.40
50.00%
Operating Profit (PBDIT) excl Other Income
-61.30
-57.70
-6.24%
Interest
0.00
0.00
Exceptional Items
-1.30
-0.80
-62.50%
Consolidate Net Profit
-26.40
-52.30
49.52%
Operating Profit Margin (Excl OI)
-109,337.50%
-151,346.00%
4,200.85%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 50.00% vs -73.33% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 49.52% vs 3.51% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Ovid Therapeutics, Inc. stock-summary
stock-summary
Ovid Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Company Coordinates stock-summary
Company Details
1460 Broadway Ste 15044 , NEW YORK NY : 10036-7329
stock-summary
Tel: 1 646 6617661
stock-summary
http://www.ovidrx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."